Current hepatitis C therapy
Authors:
Petr Husa; Svatava Snopková; Petr Husa ml.
Authors‘ workplace:
Klinika infekčních chorob LF MU a FN Brno
Published in:
Čas. Lék. čes. 2022; 161: 90-93
Category:
Review Article
Overview
Hepatitis C virus (HCV) infection is still a major cause of chronic liver diseases, with approximately 71 million chronically infected persons worldwide. People who inject drugs currently or in the past (PWID), mostly intravenously, are the main risk group among HCV chronically infected persons. The efficacy of therapy with direct acting antivirals (DAA) is almost 100 %. Currently, the main mission is to diagnose HCV infection in the most possible number of infected persons; it is in collision with poor adherence of PWID in particular.
Keywords:
chronic hepatitis C – HCV elimination – direct acting antivirals (DAA)
Sources
- European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. CPG HCV. J Hepatol 2020; 73(5): 1170–1218.
- World Health Organization. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version 2019. WHO, 2019. Dostupné na: www.who.int/news-room/fact-sheets/detail/hepatitis-c
- Selvapatt N, Ward T, Harrison L et al. The cost impact of outreach testing and treatment for hepatitis C in an urban drug treatment unit. Liver Int Off J Int Assoc Study Liver 2017; 37(3): 345–353.
- Kim H, Guerrero R, Reader SW et al. Low yield of hepatitis C infection in an outreach screening program in Harris County, Texas. Open Forum Infect Dis 2020; 7(7): ofaa19.
- Husa P ml., Husa P. Význam terénního testování v eliminaci hepatitidy C. Klinická mikrobiologie a infekční lékařství 2021; 27(1): 13–17.
- Acero Fernández D, Ferri Iglesias MJ, Buxó Pujolràs M et al. Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years. Gastroenterol Hepatol 2018; 41(1): 2–11.
- Krekulová L, Řehák V, Strunecký O, Nĕmeček V. Current situation and trends in the hepatitis C virus genotype distribution among injecting drug users in the Czech Republic. Epidemiol Mikrobiol Imunol 2009; 58(1): 84–89.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
2022 Issue 2
Most read in this issue